Telotristat etiprate

Phase 3Completed

0 watching 0 views this week📈 Rising

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Carcinoid Syndrome

Conditions

Carcinoid Syndrome

Trial Timeline

Jan 14, 2014 → Sep 12, 2018

NCT ID

NCT02026063

About Telotristat etiprate

Telotristat etiprate is a phase 3 stage product being developed by Lexicon Pharmaceuticals for Carcinoid Syndrome. The current trial status is completed. This product is registered under clinical trial identifier NCT02026063. Target conditions include Carcinoid Syndrome.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (2)

NCT ID	Phase	Status	Start	Completion	Indication
NCT02026063	Phase 3	Completed	Jan 14, 2014	Sep 12, 2018	Carcinoid Syndrome
NCT01104415	Phase 2	Completed	Jun 15, 2010	Feb 12, 2014	Carcinoid Syndrome

Competing Products

20 competing products in Carcinoid Syndrome

See all competitors

Product	Company	Stage	Hype Score
Ramucirumab + Somatostatin Analog	Eli Lilly	Phase 2	52
Pasireotide	Novartis	Phase 1	33
Pasireotide + Octreotide	Novartis	Phase 3	77
Pasireotide (SOM230)	Novartis	Phase 2	52
Octreotide + Placebo + Everolimus	Novartis	Phase 3	77
Lutathera	Novartis	Phase 2	52
EPO906 epothilone B	Novartis	Phase 2	52
Panitumumab	Amgen	Phase 2	51
Axitinib	Pfizer	Phase 2	51
Lanreotide + Placebo (for sunitinib) + Sunitinib	Pfizer	Phase 2	51
Nivolumab + Cabozantinib	Bristol Myers Squibb	Phase 2	51
bevacizumab + 5-fluorouracil + leucovorin + oxaliplatin	Sanofi	Phase 2/3	64
lanreotide Autogel (somatostatin analogue) + Sandostatin long acting release (LAR) Depot (somatostatin analogue)	Ipsen	Phase 3	74
lanreotide (Autogel formulation)	Ipsen	Approved	82
Lanreotide + Placebo	Ipsen	Phase 3	74
BIM 23A760	Ipsen	Phase 2	49
Randomized: 40 mg Paltusotine + Randomized: 80 mg Paltusotine	Crinetics Pharmaceuticals	Phase 2	47
Paltusotine + Placebo	Crinetics Pharmaceuticals	Phase 3	72
Telotristat etiprate + Placebo-matching telotristat etiprate	Lexicon Pharmaceuticals	Phase 3	72
500 mg [14C]-LX1606	Lexicon Pharmaceuticals	Phase 1	28

Other Products from Lexicon Pharmaceuticals

Sotagliflozin + PlaceboPhase 3

Telotristat etiprate + Placebo-matching telotristat etipratePhase 3

Telotristat etiprate + PlaceboPhase 3

Sotagliflozin Low Dose + Sotagliflozin High DosePhase 3

250 mg LX1033 tablets + Placebo tabletPhase 2